MedChunk
Medically reviewed

AMH Testing After Medical Treatment: What It Shows

Learn what AMH testing shows after medical treatment, how chemotherapy and other treatments may affect ovarian reserve, and what results can and cannot tell you about fertility.

By Caleb Bennett Reviewed by Dr. Irene Medical review dateNov 19, 2026 13 min read

AMH testing after medical treatment can show whether the number of small follicles in the ovaries appears lower than expected, helping assess possible changes in ovarian reserve. This can be useful after treatments that may affect the ovaries, such as certain chemotherapy regimens or pelvic radiation. However, an AMH result cannot show egg quality or confirm whether someone can become pregnant.

Why might AMH be checked after medical treatment?

Anti-Müllerian hormone (AMH) is produced by cells in small follicles inside the ovaries. These follicles contain immature eggs. Measuring AMH in the blood provides an indirect estimate of the number of follicles remaining, which is known as ovarian reserve.

Some medical treatments can affect the ovaries or the hormonal systems involved in reproductive function. After treatment, healthcare professionals may recommend AMH testing to understand whether ovarian reserve has changed and whether further fertility assessment is needed.

The National Cancer Institute explains that cancer treatments can affect fertility temporarily or permanently. The possible impact depends on factors such as the type and dose of treatment, treatment duration, age at the time of treatment, and the amount of time that has passed since treatment ended.

AMH testing may be considered after treatments or medical events such as:

  • Chemotherapy: Some chemotherapy medicines can damage ovarian follicles and reduce the number of eggs remaining.
  • Pelvic radiation therapy: Radiation involving the ovaries may affect their ability to function.
  • Ovarian or pelvic surgery: Some operations can affect ovarian tissue or the number of available follicles.
  • Previous illnesses affecting ovarian function: Certain illnesses may be associated with a lower number of growing follicles.
  • Some hormonal cancer treatments: These may affect menstrual cycles and ovarian hormone activity. Their effects differ according to the medicine and treatment plan.

Not everyone who receives medical treatment needs an AMH test. It is most useful when the result could help answer a specific question about ovarian function, fertility planning, or treatment follow-up.

What does an AMH test actually show?

After treatment, the main use of AMH testing in fertility care is to estimate the remaining supply of small ovarian follicles. The result may help healthcare professionals understand whether ovarian reserve appears reduced compared with what might be expected for a person's age.

AMH is not a direct count of eggs. It measures a hormone produced by developing follicles, so the result provides an estimate rather than an exact number.

The U.S. National Library of Medicine's MedlinePlus explains that AMH testing can estimate ovarian reserve and help predict how the ovaries may respond to fertility medicines. However, it cannot determine whether the eggs are healthy or predict whether pregnancy will occur.

A lower AMH result after treatment

A lower AMH level may suggest that fewer small follicles are producing the hormone. When the result is lower than a person's earlier measurement, it may indicate a reduction in ovarian reserve following treatment or other changes over time.

For someone who has received chemotherapy or pelvic radiation, a low result may provide useful information about possible treatment-related effects on the ovaries. It can help a fertility specialist decide whether additional tests or fertility counselling would be useful.

However, low AMH does not mean that no eggs remain. It also does not automatically mean that pregnancy is impossible. Some people with low AMH continue to ovulate or may become pregnant naturally.

A higher AMH result after treatment

A higher result generally suggests a larger number of small follicles producing AMH. It does not necessarily mean that fertility has improved or that the ovaries have fully recovered from earlier treatment.

Higher AMH may also occur in conditions associated with a larger number of small ovarian follicles, such as polycystic ovary syndrome (PCOS). In some cases, certain ovarian tumours can also produce AMH. The reason for a high result therefore matters.

An AMH result that stays low

AMH may remain below its previous level after treatment, particularly when the ovaries have experienced significant damage. This does not, by itself, establish whether ovarian function is completely lost or whether pregnancy is possible.

Age, menstrual history, the type of treatment received, and other hormone measurements help put the result into context.

Can AMH levels recover after chemotherapy or other treatment?

AMH levels can change after treatment ends. In some people, the measurements may change over the following months as ovarian activity evolves. In others, AMH may remain lower than it was before treatment.

A 2023 clinical review published in the Journal of Clinical Oncology discusses ovarian function monitoring after cancer treatments that may damage the ovaries. It reports that AMH and FSH levels can remain altered for up to two years after chemotherapy and that AMH may not return to its pretreatment level.

This means that one test taken soon after treatment may not describe the longer-term pattern. When follow-up is appropriate, healthcare professionals may compare results over time rather than relying on one measurement.

It is also important to understand that an increase in AMH does not prove that the full egg supply has returned. A changing hormone level is only one part of assessing ovarian function.

When should AMH be tested after medical treatment?

There is no single testing date that applies to everyone. The appropriate timing depends on the treatment received, the reason for testing, the person's age, and whether there are concerns about menstrual or ovarian function.

For people who have completed cancer treatment that may damage the ovaries, the 2023 clinical review recommends considering ovarian function assessment with FSH and estradiol or AMH for at least 12 to 18 months after chemotherapy. It also notes that hormone changes may continue for up to two years after treatment stops.

This is a consideration for people who have received potentially damaging cancer treatment, not a requirement for everyone who has undergone medical therapy. The oncology team and fertility specialist can decide whether testing is appropriate and how often it should be repeated.

Why might repeat testing be recommended?

A repeat measurement may help show whether AMH has remained low, increased, or changed further. This can be useful when the first test was performed relatively soon after treatment or when fertility planning depends on understanding current ovarian reserve.

When comparing results, it helps to know which laboratory performed the tests. Laboratories may use different testing methods, and this can affect the reported values. The same laboratory and testing method, when available, can make comparisons easier to interpret.

How is AMH testing performed after treatment?

AMH testing is a blood test. A healthcare professional collects a small blood sample, usually from a vein in the arm, and the laboratory measures the amount of AMH in the sample.

Unlike some other reproductive hormone tests, AMH can generally be measured at different points in the menstrual cycle. The test usually does not require special preparation or fasting.

The American Society for Reproductive Medicine (ASRM) identifies AMH as an important marker of ovarian reserve. It also explains that AMH and an ultrasound measurement called the antral follicle count can help estimate ovarian response during fertility treatment.

Depending on the reason for testing, a healthcare professional may also recommend:

  • FSH testing: Follicle-stimulating hormone can provide additional information about ovarian function.
  • Estradiol testing: This hormone measurement may help with the interpretation of FSH results.
  • Antral follicle count: An ultrasound examination estimates the number of small follicles visible in the ovaries.
  • Menstrual history: Changes in period frequency or the absence of periods may provide important information about ovarian function.

These tests assess different aspects of reproductive health. The results are considered together rather than treating AMH as a complete picture of ovarian function.

What AMH cannot tell you after treatment

AMH is useful for estimating ovarian reserve, but it has important limitations. A result should not be treated as a direct measure of fertility or as a prediction of whether someone will have a successful pregnancy.

It does not measure egg quality

AMH provides information about the quantity of the remaining follicle pool, not the genetic health or developmental quality of individual eggs. Age is an important factor when assessing reproductive outcomes.

It cannot confirm whether natural pregnancy is possible

A low AMH result does not establish infertility. Similarly, a normal or high result does not guarantee that pregnancy will occur. Natural conception also depends on factors such as ovulation, fallopian tube function, sperm health, and age.

It does not predict the exact time of menopause

AMH generally decreases as ovarian reserve declines with age. However, a single result cannot reliably establish when menopause will occur. A low result should therefore not be used on its own to predict the timing of menopause.

It cannot assess every effect of treatment on ovarian function

Ovarian hormone production, menstrual activity, and the number of available follicles are related but are not identical measures. Someone may need additional blood tests or an ultrasound even when an AMH result is available.

The ASRM explains that ovarian reserve tests are more useful for estimating how many eggs may be collected during fertility treatment than for predicting pregnancy or live birth independently of age.

How AMH results may guide fertility planning

When someone wishes to have children after medical treatment, AMH may help a fertility specialist estimate how the ovaries could respond to fertility medicines. This information can be useful when discussing options such as ovarian stimulation, egg retrieval, or embryo freezing.

For example, a lower AMH level may suggest that fewer eggs could be collected during an IVF stimulation cycle. A higher level may indicate a stronger response, which can influence the medicine dose selected by the fertility specialist.

However, the number of eggs collected is not the same as the chance of having a baby. Egg quality, age, sperm factors, embryo development, and other treatment-related factors also influence the outcome.

People who are considering pregnancy after cancer treatment should also discuss the safest timing with their oncology team. The type of cancer, the medicines used, the possibility of further treatment, and the person's overall recovery may affect when pregnancy can be considered.

AMH testing for monitoring certain ovarian tumours

AMH has another use that is different from measuring fertility or ovarian reserve. Some ovarian tumours produce AMH, so healthcare professionals may use the hormone as one of the markers when monitoring selected cases.

According to MedlinePlus, a decrease in AMH during treatment for certain ovarian cancers may suggest that treatment is working, while an increase may indicate that treatment is not working as expected or that cancer has returned.

This use applies only when the tumour is known to produce AMH. AMH is not a general test for detecting or monitoring every type of ovarian cancer. It must be interpreted alongside the relevant clinical assessment, imaging, and other tumour markers when indicated.

It is therefore important to understand why the test was ordered. An AMH result used to assess fertility has a different meaning from one used to monitor an AMH-producing tumour.

When should you discuss an AMH result with a specialist?

It is useful to review an AMH result with the doctor who managed the treatment or a reproductive specialist, particularly when future pregnancy is important or menstrual changes have developed.

Arrange a clinical discussion when:

  • Menstrual periods become irregular or stop after treatment.
  • There are new hot flashes, night sweats, or vaginal dryness after treatment that may have affected ovarian hormone production.
  • An AMH result is substantially different from a measurement taken before treatment.
  • Pregnancy is being considered after chemotherapy, radiation, or ovarian surgery.
  • There is uncertainty about whether an AMH test is being used for fertility assessment or tumour monitoring.

The treating team can review the treatment history, age, symptoms, hormone results, and ultrasound findings to explain what the measurement means and whether further follow-up is needed.

Ultimately, AMH testing can provide useful information about ovarian reserve after medical treatment, but it is one part of a wider assessment. Understanding the reason for testing and comparing the result with the person's medical and reproductive history are essential for making informed decisions.

Frequently Asked Questions

Common questions about interpreting AMH levels and ovarian function after medical treatment.

Does low AMH after chemotherapy mean I cannot get pregnant?

No. Low AMH may indicate a reduced ovarian reserve, but it does not prove that pregnancy is impossible. Some people with low AMH continue to ovulate and may conceive naturally. Age, menstrual function, other reproductive factors, and the type of treatment received are also important when assessing fertility.

Can AMH return to its previous level after medical treatment?

AMH levels can change after treatment, but they do not always return to their pretreatment levels. After some cancer treatments, changes may continue for months or even up to two years. A higher reading does not necessarily mean that ovarian reserve has fully recovered.

How soon after chemotherapy should I have an AMH test?

There is no single testing date for everyone. For people who have received cancer treatment that may damage the ovaries, a clinical review discusses considering ovarian function assessment for at least 12 to 18 months after chemotherapy. The treating team can recommend an appropriate schedule based on the treatment and individual circumstances.

Can AMH testing show whether ovarian cancer treatment has worked?

In selected cases, yes. Certain ovarian tumours produce AMH, and changes in the hormone may help monitor treatment response. A falling level may suggest that treatment is working, while a rising level may raise concern about treatment response or recurrence. This approach does not apply to every type of ovarian cancer and must be interpreted with other clinical findings.

Citations

  1. MedlinePlus – Anti-Müllerian Hormone Test
  2. National Cancer Institute – Female Fertility and Cancer Treatment
  3. Journal of Clinical Oncology – Cancer Treatment-Related Ovarian Dysfunction in Women of Childbearing Potential: Management and Fertility Preservation Options
  4. American Society for Reproductive Medicine – Testing and Interpreting Measures of Ovarian Reserve: A Committee Opinion
  5. Gloucestershire Hospitals NHS Foundation Trust – Anti-Mullerian Hormone (AMH) Assessment
Share this article